Carbapenem–valproic acid derivative drug-drug interactions: Evaluation of a pharmacist-facing OurPractice Advisory

Clicks: 1
ID: 338154
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #245 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose The purpose of this quality improvement evaluation was to describe implementation and postimplementation experience with a pharmacist-facing OurPractice Advisory (OPA) within the Epic electronic health record designed to identify concurrent carbapenem antibiotic and valproic acid (VPA) derivative therapy. Summary A pharmacist-facing OPA was developed to identify selected clinical scenarios involving carbapenem antibiotics and VPA derivatives, including scenarios involving active inpatient medication orders and prior-to-admission medication list entries. A retrospective review was conducted for hospitalized patients with OPA activations over a 10-month period. The OPA appeared for 30 hospitalized patients. The most common activation scenario was a carbapenem ordered in the presence of an already verified inpatient VPA derivative order, occurring in 19 patients (63.3%). The most common VPA derivative indication was mood stabilization in 12 patients (40%), followed by a seizure-related indication in 9 patients (30%). The median (IQR) time to pharmacist order decision was 21.5 (5.25-51.25) minutes. Formal infectious diseases consultation and neurology consultation occurred in 23 (76.7%) and 10 (33.3%) patients, respectively. Antibiotic therapy was switched from a carbapenem to a different antibiotic in 14 cases (46.7%), VPA derivative therapy was held, discontinued, or not verified in 7 cases (23.3%), and both agents were continued without change in 8 cases (26.7%). Conclusion Implementation of a pharmacist-facing OPA provided a structured process for identifying and documenting selected carbapenem–VPA derivative drug-drug interaction scenarios during pharmacist order verification. Postimplementation review identified opportunities for refinement, including reduction of repetitive activations, clarification of acknowledgment options, and consideration of earlier prescriber-facing clinical decision support.
Reference Key
openalex_W7225124831 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kyle Schuchter, Allison Layton, Casey C. May
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag374
URL
https://doi.org/10.1093/ajhp/zxag374
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.